General Information of Drug (ID: DM5T401)

Drug Name
CNX-011 Drug Info
Synonyms GPR 40 agonists (type 2 diabetes); CNX-011-67; GPR 40 agonists (type 2 diabetes), Connexios LifeSciences; G-protein coupled receptor 40 agonists (type 2 diabetes), Connexios Life Sciences
Indication
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Investigative [1]
Cross-matching ID
TTD Drug ID
DM5T401

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TAK-875 DMIM5AP Type-2 diabetes 5A11 Phase 3 [2]
Fasiglifam hemihydrate DMTGYSO Type-2 diabetes 5A11 Phase 3 [3]
PBI-4050 DMPXK27 Idiopathic pulmonary fibrosis CB03.4 Phase 2 [4]
P-1736 DMEYQPN Diabetic complication 5A2Y Phase 2 [5]
JTT-851 DMED5J6 Type-2 diabetes 5A11 Phase 2 [6]
SHR0534 DMGFTAI Type 2 diabetes 5A11 Phase 1 [7]
LY-2881835 DM5EXJV Type-2 diabetes 5A11 Phase 1 [6]
P11187 DMXZOI0 Type-2 diabetes 5A11 Phase 1 [6]
CPL207-280CA DMFMGZR Type 2 diabetes 5A11 Phase 1 [7]
LY2922470 DMGLTE2 Type 2 diabetes 5A11 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Free fatty acid receptor 1 (GPR40) TTB8FUC FFAR1_HUMAN Agonist [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 225).
2 Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81.
3 A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280.
4 Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
5 Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946.
6 Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
7 Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
8 The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.